A REVOLUTIONARY ADVANCEMENT IN IMMUNOLOGY
VEL Sciences is an early-stage, pre-clinical biopharma developing Immunotherapeutics against Cancer, antigenically variable pathogens (AVPs), and infectious diseases.
Introduction
What if you could use innovative technology that would:
- Accelerate the "speed to market" of a vaccine or immunotherapeutic;
- save up to 75% of time and expense of R&D;
- Greatly reduce or eliminate immune escape and proactively increase long-term protective immunity.
VEL Sciences has the revolutionary technology.
- VELs, consisting of millions of permutations, induce the most diverse immune responses, reflecting the evolving antigenic landscape of viruses and cancer cells;
- VELs are then embedded into the vaccine carrier and introduced into the body;
- VELs trigger B-cell and T-cell effector/memory immune responses, thus avoiding “immune escape”, and recognize new antigenic variants through vaccine-induced memory response.
EFFICIENCY
VELs can potentially reduce the time and cost of vaccine development by 70-80% compared to other methods.
According to published data, the average vaccine costs approximately $500 million – $2 Billion to bring to market. VELs will significantly reduce the time-cost of capital outlay and take the product research and development phase down from years to months, contributing to the highest possible ROI for commercial partners.
UNIVERSAL SOLUTION
VEL immunotherapeutics are off-the-shelf, universal solutions for fast and efficacious immune-based therapies covering many diseases and Cancer. A powerful stand-alone or combination therapy for enhancing immune checkpoint inhibitors (ICI) and adoptive T-cell therapy (ACT) cancer treatments.
BEST-IN-CLASS
The patented Variable Epitope Library (VEL) is proven to elicit strong and sustained tumor-specific protective T-cell responses in animal models leading to best-in-class data.
As a qualitatively new class of immunotherapeutics, VELs may make a decisive contribution to the success of vaccine clinical trials that have failed previously.
CARRIER COMPATIBILITY
VELs are compatible and will work universally with virtually all vaccine delivery systems such as synthetic peptides, DNA, mRNA, viral vectors or nanostructures, and DC-based vaccines.
"The universal nature of VEL-based immunotherapeutics targeting antigenically variable pathogens and practically all types of cancer is a clear advantage."
HOW IT WORKS
Our VEL platform is the first technology to address the immune escape capability of antigenically variable targets at the epitope level and provides a strategy to break immune tolerance by inducing potent, long-lasting T and B-cell responses.
Our proprietary Variable Epitope Library (VEL) platform has proven to elicit strong and sustained tumor-specific protective T cell responses in animal models. These responses result in highly diverse T cell populations and position VEL as a powerful stand-alone and combination therapy for enhancing immune checkpoint inhibitors (ICI) and adoptive T cell therapy (ACT) cancer treatments.
VELs are compatible and will work universally with virtually all vaccine delivery systems, such as synthetic peptides, DNA, mRNA, viral vectors or nanostructures, and DC-based vaccines.
VEL is a universal platform applicable to numerous therapeutic areas.
The simultaneous presentation of a large number of epitope variants by immunization with VEL immunotherapeutics may recall past responses, induce responses against antigens present during immunization, and induce T cells capable of recognizing future mutated antigens, thus reducing the chances of immune escape. In this manner, VEL immunogens are in a class all their own.
